Aqemia bets physics-driven AI can deliver novel drugs, not faster me-too molecules

At the J.P. Morgan Healthcare Conference in San Francisco, the AI drug discovery pitch is familiar: shrink timelines, automate bottlenecks, take a process that spans a decade-plus and billions of dollars and compress it. For years, the industry has treated speed and cost as the headline metrics. The numbers, however, still point in the wrong… The post Aqemia bets physics-driven AI can deliver novel drugs, not faster me-too molecules appeared first on Drug Discovery and Development.

Continue reading →